Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
To see if certain variations in the CYP2B6 gene contribute to differences in plasma drug
levels and central nervous system side affects in people who take nevirapine or efavirenz.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center